Having recognized the palmitoylation motif of APLNR, we made a brief substrate sequence to competitively inhibit the palmitoylation of endogenous APLNR. This aggressive peptide, which targets the APLNR palmitoylation site in combination with morphine, can inhibit the development of NCP, including pain incidence, microglial activation, and inflammatory component launch https://conolidine66421.elbloglibre.com/26822413/the-best-side-of-block-pain-receptors-with-proleviate